Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T Dec 10 | 2020What is Behind Ide-cel's mPFS and mOS Disparity? Thoughts on Ide-cel's Launch Messaging and List Price; bb21217’s Manufacturing Updates; bluebird bio ASH Investor EventAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19, CD22 Dec 08 | 2020Clinical Updates and Market Opportunities for AUTO1 and AUTO3; ASH Day 3 Autolus Investor EventAccess Free BlastFree
Posted in: BCMA, CAR-T Dec 08 | 2020Could Cilta-cel Become the BCMA CAR-T of Choice in 2021? ASH Day 3 Legend Investor EventAccess Free BlastFree
Posted in: Autologous, BCMA Dec 07 | 2020AUTO3 Outpatient Data in the Ph1/2 ALEXANDER Study; Updated Results for Liso-cel in the TRANSCEND CLL 004 Trial; ZUMA-5 Primary Analysis and Re-treatment; ASH Day 3Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Dec 06 | 2020ZUMA-12 Reports an 85% ORR in 1L DLBCL; Liso-cel’s Safety Profile vs Kymriah and Yescarta; Comparison of OOS Use of CD19 Commercial CAR-Ts; ASH Day 2Access Free BlastFree
Posted in: Allogeneic, Autologous, CD19, CD22 Dec 06 | 2020Kymriah Demonstrates a Favorable Safety Profile in FL; Updated Results for AUTO1's Ph1 ALLCAR19 Trial in ALL and iNHL; Initial Data from Cellectis's UCART22 Ph1 BALLI-01 Study; ASH Day 1 EncoreAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CAR-T Dec 05 | 2020Updated Results for ALLO-715 from ASH and Allogene's Investor Call; CARsgen Fully Human BCMA CART CT053 Reports a 94% ORR in MM; Poseida Modifies Their P-BCMA-101 CAR-T Manufacturing Process; ASH Day 1 EncoreAccess Free BlastFree
Posted in: Allogeneic, Autologous, BCMA, CD19 Dec 05 | 2020CARTITUDE-1 Demonstrates Potential Best-in-Class Efficacy; Ide-cel’s CRB-401 Study Updates mDoR Data; Clinical and Manufacturing Updates for bb21217; A Comparison of Tecartus vs Liso-cel in MCL; Day 1 ASH 2020 HighlightsAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Dec 04 | 2020Interim Results from PBCAR0191’s Ph1/2a Trial; Updated Clinical Strategies to Improve Response; New Details Disclosed for PBCAR19B Stealth CAR-T; Precision’s Pre-ASH Investor Call SummaryAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Dec 02 | 2020A New Ph1 Trial for Precision's CD19 Allogeneic CAR-T PBCAR19B; Could PBCAR19B Knock Down B2M Expression to Enhance Persistence?Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Nov 27 | 2020UPDATED: Novartis on Track to File Kymriah in R/R FL and 2L DLBCL in 2021; Meet the Management Investor Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T Nov 19 | 2020Will FDA Virtually Inspect for Liso-cel US Approval? Celgene CVR Hangs in the BalanceAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD19 Nov 18 | 2020FDA Lifts Clinical Hold for Cellectis’s UCARTCS1 Ph1 MELANI-01 Trial; No Update on Protocol ChangesAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Nov 17 | 2020Thoughts on Liso-cel’s Incomplete FDA Review; PDUFA Analysis may have Possible Implications for CAR-T CMOs and Manufacturing PartnershipsAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Nov 16 | 2020Cilta-cel’s ASH 2020 Clinical Updates; Global Regulatory Filings Remain on Track; Allogeneic BCMA CAR-T Enters into Ph1 Trial; Legend’s Q3 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Nov 16 | 2020Ziopharm’s TCR-T Program at the NCI Continues to Face Delays; MD Anderson Hotspot TCR-T IND Filing on Track for 2021; Q3 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, CAR-T, CD123, CD22, CS1 Nov 16 | 2020UCART22 and UCART123 Clinical Updates to be Presented at ASH 2020; UCARTCS1 Remains on Clinical Hold; Cellectis Q3 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous Nov 16 | 2020Legend Appoints a New CEO and Chairperson; New Ph1 Pipeline Updates Including an Allogeneic BCMA CAR-TAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Nov 10 | 2020Expanded Collaboration with Servier; PBCAR0191 Clinical Update Expected in Q4 2020; Precision’s Q3 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19, CD22 Nov 06 | 2020AUTO1 and AUTO3 Clinical Updates to be Presented at ASH 2020; AUTO3 Pivotal Trial Likely in H1 2021; Autolus Q3 2020 Earnings Call SummaryAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.